期刊文献+

西洛他唑对老年下肢动脉硬化闭塞症患者超敏C反应蛋白、血脂及基质金属蛋白酶-9的影响 被引量:6

Effects of cilostazol on the highsensitive creactive protein,blood lipid and matrix metalloproteinase-9 in elderly patients with lower extremity arteriosclerosis obliterans
下载PDF
导出
摘要 目的探讨西洛他唑对老年下肢动脉硬化闭塞症患者超敏C反应蛋白(Hs-CRP)、血脂及基质金属蛋白酶9(MMP-9)的影响。方法选择老年下肢动脉硬化闭塞症患者60例,随机分为基本治疗组和西洛他唑组,同时以30例健康体检人员作为对照组。观察治疗后各组Hs-CRP、血脂及MMP-9的变化。结果治疗后基本治疗组血脂变化不明显,西洛他唑组总胆固醇(TC)水平明显下降,高密度脂蛋白胆固醇(HDL-C)显著上升。治疗后2组Hs-CRP、MMP-9水平均明显下降,西洛他唑组下降幅度大于基本治疗组。结论西洛他唑通过降低炎性因子浓度,调解血脂,降低Hs-CRP、MMP-9等途径改善下肢血管病变患者症状。 Objective To observe the effects of Cilostazol on the highsensitive creactive protein (Hs-CRP), blood lipid and matrix metalloproteinase-9 (MMP-9) in elderly patients with lower extremity arteriosclerosis obliterans. Meth- ods Sixty aged patients with lower extremity arteriosclerosis obliterans were randomly assigned to conventional therapy group( group A) and Cilostazol group( group B). Thirty healthy people were selected as the normal group. Hs-CRP, blood lipid and MMP-9 in blood serum were measured be fore and after therapy. Results After therapy the level of blood lipid in blood serum of group A had not a marked change. But the level of high density lipoprotein of group B increased obvious- ly. At the same time the level of Hs-CRP and MMP-9 decreased. The degree of decrease in group B was more significant than that in group A. Conclusions The therapy of Cilostazol can adjust blood lipid metabolism, decrease inflammatory factors and improve symptoms.
出处 《实用老年医学》 CAS 2012年第4期285-287,共3页 Practical Geriatrics
关键词 西洛他唑 动脉硬化闭塞症 超敏C反应蛋白 血脂 基质金属蛋白酶-9 cilostazol arteriosclerosis obliterans highsensitive creactive protein blood lipid matrix metallopro-teinase-9
  • 相关文献

参考文献3

二级参考文献23

  • 1丁国林,丁欣.糖尿病并发冠心病的机制和临床特点[J].国外医学(老年医学分册),2006,27(3):143-143. 被引量:1
  • 2The DECODE study group on behalf of the European diabetes Epidemiology group.Glucose tolerance and cardiovascular mortality[J].Arch Int Med,2001,161(1):397-404.
  • 3Bartnik M,Ryden L,Ferrari R,et al.The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe:the Euro Heart Survey on diabetes and the heart[J].Eur Heart J,2004,25(1):1880-1890.
  • 4Choi KM,Lee KW,Kim SG,et al.Inflammation,insulin resistance,and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus[J].J Clin Endocrinol Metab,2005,90(1):175-180.
  • 5Siqueira AF,Almeida-Pititto B,Ferreira SR.Cardiovascular disease in diabetes mellitus:classical and non-classical risk factors[J].Arq Bras Endocrinol Metabol,2007,51(2):257-267.
  • 6Adler AI.Cardiovascular risk reduction in diabetes:underemphasised and overdue.Messages from major trials[J].Clin Med,2001,1 (6):472-477.
  • 7Jakobisiak M,Bruno S,Skierski JS,et al.Cell cycle-specific effects of lovastatin[J].Proc Natl Acad Sci USA,1991,88(9):3628-3632.
  • 8Bell DS.Diabetic cardiomyopathy,a unique entity or a complication of coronary artery disease[J].Diabetes Care,1995,18(5):708-714.
  • 9胡大一,马长生,主编.心脏病学实践[M].北京:人民卫生出版社,2006:398.
  • 10黄元铸.糖尿病合并冠心病研究进展[J].实用老年医学,2007,21(5):292-293. 被引量:2

共引文献43

同被引文献61

  • 1范利,朱冰坡,曹剑,李小鹰,曾强.普罗布考对老年下肢动脉硬化症患者血管内皮活性因子及炎性因子的影响[J].微循环学杂志,2006,16(3):55-57. 被引量:5
  • 2赵晓宁.下肢动脉硬化闭塞症的诊断方法[J].现代生物医学进展,2007,7(4):629-630. 被引量:17
  • 3Takaoka H, Takeuchi M, Odake M, et al. Comparison of hemodynamic determinants for myocardial oxygen consumption under different contractile states in human ven- tricle [ J ]. Circulation, 1993, 87 ( 1 ) : 59-69.
  • 4Hoeft A, Sonntag H, Stephan H, et al.Validation of myocar- dial oxygen demand indices in patients awake and during an- esthesia [ J ]. Anesthesiology, 1991,75 ( 1 ) : 49-56.
  • 5Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood In- stitute-Sponsored Women's Ischemia Syndrome Evaluation ( WISE ) [ J ]. Circulation, 2004,109 (6) :726-732.
  • 6Asegaonkar SB, Marathe A, Tekade ML, et al. High-sensi- tivity C-reactive protein : a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile [ J ]. J Diabetes Complications, 2011,25 (6) : 368-370.
  • 7Kassim RA, Saleh KJ, Badra M, et al.Thromboembolic com- plications after total hip arthroplasty[ J]. J South Orthop As- soc,2003, 12(2): 103-105.
  • 8Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application of clinical and public health practice:a statement for heahhcare professionals from the Centers for Disease Control and pre- vention and the Americari Heart Association [ J ].Circulation, 2003,107 (3) : 499-511.
  • 9Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clin- ical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Pre- vention and the American Heart Association [ J ]. Circulation, 2003,107(3) :499-511.
  • 10de la Fuente Tomero E, Garutti Martinez I, Gutierrez Tonal B, et al. Comparison of hemostatic markers under different techniques for anesthesia-analgesia in total hip or knee re- placement[ J ]. Rev Esp Anestesiol Reanim, 2010,57 (6) : 333-340.

引证文献6

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部